Clinical trials: PE - Pulmonary Thromboembolism
Submassive Pulmonary Embolism
ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism
The ULTIMA study is intended to prove that in patients with pulmonary embolism and a right ventricular end diastolic diameter to left ventricular end diastolic diameter ratio ≥1 (RV/LV ratio) will benefit from treatment with…
- Trial name
- ULTIMA (NCT01166997)
- Testing
- EkoSonic Endovascular System, Unfractionated heparin
- Where
- 10 sites in Germany, Switzerland
- Volunteers
- 59 people
- Sponsor
- Boston Scientific Corporation
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
Stent-Retriever for Acute Massive Pulmonary Embolism (SRAME)
To evaluate treatment outcomes of patients diagnosed with pulmonary embolism.
- Trial name
- SRAME (NCT05992168)
- Testing
- Stent-Retriever
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Suzhou Zenith Vascular SciTech Limited
Venous Thromboembolism, Deep Vein Thrombosis (DVT)
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism
- Trial name
- NCT00986154
- Testing
- edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
- Where
- 454 sites in United States, Argentina and 36 more
- Volunteers
- 8,292 people
- Sponsor
- Daiichi Sankyo
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT)
Cancer Venous Thromboembolism (VTE)
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major…
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
- Trial name
- NCT02073682
- Testing
- Edoxaban, Dalteparin, Low molecular weight heparin
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 1,046 people
- Sponsor
- Daiichi Sankyo
Venous Thromboembolism
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the…
- Trial name
- MAGELLAN (NCT00571649)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 676 sites in United States, Argentina and 51 more
- Volunteers
- 8,101 people
- Sponsor
- Bayer
Venous Thromboembolism
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
RE-COVERY is a large, multi-national, multi-center observational study based on new data collection. The study will enroll and characterize patients within 30 days of being diagnosed with an acute DVT and/or PE.
- Trial name
- NCT02596230
- Where
- 222 sites in United States, Argentina and 35 more
- Volunteers
- 7,797 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Embolism, Thrombotic Disease
Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
This is a Phase 1b, double-blind (participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, efficacy, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT02923115
- Testing
- DS-1040b, Enoxaparin
- Where
- 46 sites in United States, Austria and 6 more
- Volunteers
- 134 people
- Sponsor
- Daiichi Sankyo
Pulmonary Embolism
Multicenter, Nonrandomized, Prospective Study of Pulmonary Embolism Removal With the AngioJet 6F Ultra System
The purpose of this European Post Market Follow-up Plan is designed to evaluate the safety, efficacy, adverse events and any new information that may surface regarding the use of the AngioJet Ultra PE Thrombectomy Catheter System…
- Trial name
- PERFUSE (NCT01638468)
- Testing
- AngioJet Ultra PE Thrombectomy System
- Where
- 7 sites in Germany, Italy and 2 more
- Volunteers
- 7 people
- Sponsor
- Boston Scientific Corporation
Thrombosis, Venous
The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
The primary objective of this study is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism [VTE] (i.e., Pulmonary thromboembolism [PE] and Deep Vein Thrombosis [DVT])) and safety of…
- Trial name
- NCT00911157
- Testing
- Fondaparinux sodium, unfractionated heparin (UFH)
- Where
- 24 sites in Japan
- Volunteers
- 39 people
- Sponsor
- GlaxoSmithKline
Prevention, Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
The purpose of this study is to assess if 10 mg Bay 59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
- Trial name
- RECORD 3 (NCT00361894)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 143 sites in Austria, Belgium and 17 more
- Volunteers
- 2,531 people
- Sponsor
- Bayer
Venous Thromboembolism (VTE)
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2.
- Trial name
- ROXI-CAT-II (NCT07493304)
- Testing
- REGN7508, Apixaban
- Where
- 13 sites in United States, Bulgaria and 3 more
- Volunteers
- 1,600 people
- Sponsor
- Regeneron Pharmaceuticals
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
FlowTriever All-Comer Registry for Patient Safety and Hemodynamics
To evaluate the safety and effectiveness of the FlowTriever System for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism (PE).
- Trial name
- FLASH (NCT03761173)
- Testing
- FlowTriever System, Anticoagulation Agents
- Where
- 81 sites in United States, Austria and 7 more
- Volunteers
- 1,200 people
- Sponsor
- Inari Medical
Pulmonary Embolism
Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in the treatment of pulmonary embolism (PE) and the prevention of the occurrence and the recurrence…
- Trial name
- NCT01516814
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Unfractionated heparin, Warfarin
- Where
- 31 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Bayer
Pulmonary Embolism
Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China
EINSTEIN PE study demonstrated that rivaroxaban is at least as effective as the current standard therapy with 51% relative risk reduction of major bleeding (1.1% vs.
- Trial name
- XAPEC (NCT03410706)
- Testing
- Rivaroxaban(Xarelto, BAY 59-7939)
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Bayer
Pulmonary Embolism (PE), Pulmonary Thromboembolism
The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung
A study based on a chart review of participants that presented with a sudden blood clot in the lung
- Trial name
- NCT03595891
- Testing
- Non-Interventional
- Where
- United Kingdom
- Volunteers
- 660 people
- Sponsor
- Bristol-Myers Squibb
Cancer-Associated Thrombosis (CAT)
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
- Trial name
- ROXI-CAT-I (NCT07410117)
- Testing
- REGN7508
- Where
- 23 sites in United States, Georgia and 1 more
- Volunteers
- 1,120 people
- Sponsor
- Regeneron Pharmaceuticals
Pulmonary Embolism, Venous Thromboembolism
Celect Vena Cava Filter Clinical Trial
The clinical study will collect data to verify the safety and performance of the Cook Celect Filter in the prevention of pulmonary embolism (PE) in patients with a temporary or permanent high risk of thromboembolism.
- Trial name
- NCT00470626
- Testing
- Celect Vena Cava Filter
- Where
- 8 sites in Australia, Germany and 3 more
- Volunteers
- 129 people
- Sponsor
- Cook Group Incorporated
Pulmonary Embolism, Pulmonary Thromboembolism
The PERSEVERE Study
Randomized Controlled Trial of High-Risk Pulmonary Embolism Comparing FlowTriever System vs. Standard of Care
- Trial name
- NCT06588634
- Testing
- FlowTriever System, Standard of Care
- Where
- 33 sites in United States, France and 4 more
- Volunteers
- 200 people
- Sponsor
- Inari Medical
Pulmonary Embolism, Acute Pulmonary Embolism
FlowTriever Pulmonary Embolectomy Clinical Study
Evaluate the safety and effectiveness of the FlowTriever System for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism.
- Conditions
- Pulmonary Embolism, Acute Pulmonary Embolism, Submassive Pulmonary Embolism, Massive Pulmonary Embolism
- Trial name
- FLARE (NCT02692586)
- Testing
- FlowTriever System
- Where
- 18 sites in United States
- Volunteers
- 106 people
- Sponsor
- Inari Medical
Symptomatic Venous Thromboembolism (VTE)
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA).
- Trial name
- ROXI-ASPEN (NCT07213778)
- Testing
- REGN7508, Acetylsalicylic Acid (ASA)
- Where
- 51 sites in United States, Greece and 3 more
- Volunteers
- 2,000 people
- Sponsor
- Regeneron Pharmaceuticals